Core Viewpoint - Rosen Law Firm is reminding investors who purchased CTO Realty Growth, Inc. securities between February 18, 2021, and June 24, 2025, of the upcoming lead plaintiff deadline on October 7, 2025 [1]. Group 1: Class Action Details - Investors who purchased CTO Realty securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by October 7, 2025 [3]. - The lawsuit alleges that CTO Realty Growth made false and misleading statements regarding the sustainability of its dividends and the profitability of its Ashford Lane property, leading to overstated business and financial prospects [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked in the top 4 for securities class action settlements since 2013 and recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Core Viewpoint - A lawsuit has been filed against Lineage, Inc. and its senior executives for potential violations of federal securities laws related to its IPO and subsequent financial performance [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Eastern District of Michigan, specifically titled City of St. Clair Shores Police and Fire Retirement System v. Lineage, Inc., et al., No. 2:25-cv-12383 [2]. - Investors who purchased stock during Lineage's IPO on or about July 25, 2024, are represented in the lawsuit, which asserts claims under Sections 11 and 15 of the Securities Act of 1933 [2][4]. Group 2: Company Overview - Lineage, Inc. operates as a cold storage-focused real estate investment trust (REIT), owning and managing temperature-controlled storage facilities for perishable products [3]. - The company claimed in its IPO documents that it had "consistent cold chain demand" and strong cash flows, even during economic downturns [4]. Group 3: Financial Performance and Market Reaction - Following the IPO, Lineage's stock price has significantly declined from an initial price of $78 per share to around $40 per share, approximately half of its IPO value [5]. - In its fiscal Q4 2024 results announced on February 26, 2025, Lineage indicated that customers were "unwinding" excess inventory, returning to a more normal seasonal pattern [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Altimmune, Inc. securities between August 10, 2023, and June 25, 2025, of the October 6, 2025, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - A class action lawsuit has been filed against Altimmune, and investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2] - To join the class action, investors can submit a form online or contact the law firm directly for more information [2][5] - The lawsuit claims that Altimmune misrepresented the results of its IMPACT Phase 2b MASH trial, failing to meet a key statistical significance marker related to fibrosis reduction [4] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3] - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [3]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation Details - The investigation is prompted by a press release from Tandem Diabetes Care on August 7, 2025, regarding a voluntary medical device correction for select t:slim X2 insulin pumps, which indicated a potential speaker-related issue that could lead to insulin delivery discontinuation [3]. - Following the announcement, Tandem Diabetes' stock experienced a significant decline of 19.9% on the same day [3]. Group 2: Class Action Information - Shareholders who purchased Tandem Diabetes Care securities may be eligible for compensation through a class action lawsuit, with no out-of-pocket fees or costs due to a contingency fee arrangement [2]. - Interested parties can join the class action by visiting the provided link or contacting the law firm directly for more information [2]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and consistently ranking in the top 4 for securities class action settlements since 2013 [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for its clients [4].

Group 1 - A lawsuit has been filed against Charter Communications, Inc. and certain senior executives for potential violations of federal securities laws [1][2] - The lawsuit claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, with a deadline for investors to seek lead plaintiff status by October 14, 2025 [2] - Charter is a leading broadband and cable operator that participated in the FCC's Affordable Connectivity Program, which ended in June 2024 due to lack of federal funding, leading to customer declines [3] Group 2 - During the relevant period, Charter communicated to investors that it was managing the impact of the Affordable Connectivity Program's end, claiming the effects were behind them [4] - Contrary to these statements, Charter continued to experience declines in internet customers and revenue following the program's termination [4] - On July 25, 2025, Charter reported a decrease of 117,000 total internet customers in Q2 2025, with approximately 50,000 disconnects attributed to the end of the program, resulting in an 18.4% stock price decline [5]

Core Viewpoint - Rosen Law Firm is reminding purchasers of Lineage, Inc. common stock about the September 30, 2025 lead plaintiff deadline for a class action lawsuit related to the company's July 2024 IPO [1]. Group 1: Class Action Details - Investors who purchased Lineage common stock may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by September 30, 2025 [3]. - The lawsuit claims that the registration statement was false and/or misleading, failing to disclose significant issues affecting Lineage's business operations and financial results [5]. Group 2: Allegations Against Lineage - The lawsuit alleges that Lineage experienced a sustained weakening in customer demand due to increased cold-storage supply and destocking of excessive inventory by customers [5]. - It is claimed that Lineage implemented unsustainable price increases prior to the IPO, which could not be maintained in the face of weakening demand [5]. - The company reportedly could not counteract adverse trends through operational efficiencies or competitive advantages, leading to stagnant or falling revenue, occupancy rates, and rent prices [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - Rosen Law Firm has been recognized for its leadership in securities class action settlements, ranking No. 1 in 2017 and consistently in the top 4 since 2013 [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Biohaven Ltd. securities during the specified Class Period of the upcoming lead plaintiff deadline on September 12, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Biohaven securities between March 24, 2023, and May 14, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the September 12, 2025 deadline [2]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for the number of settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3]. Group 3: Case Allegations - The lawsuit alleges that Biohaven made false and misleading statements regarding the regulatory prospects of its drug troriluzole for treating spinocerebellar ataxia and the efficacy of BHV-7000 for bipolar disorder, which were overstated [4]. - The lawsuit claims that these misrepresentations likely had a significant negative impact on Biohaven's business and financial condition once the truth was revealed, resulting in investor damages [4].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Encompass Health Corporation due to allegations of materially misleading business information [1] Group 1: Investigation and Allegations - The investigation is prompted by an article published by The New York Times, which reported serious incidents of patient harm and below-average performance on key safety measures at Encompass Health's rehab hospitals [3] - Following the publication of the article, Encompass Health's stock price dropped by 10.3% on July 15, 2025 [3] Group 2: Class Action Details - Investors who purchased Encompass Health securities may be entitled to compensation through a class action lawsuit, with no out-of-pocket fees due to a contingency fee arrangement [2] - Interested investors can join the class action by submitting a form or contacting the Rosen Law Firm directly [2] Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field [4] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Encompass Health Corporation due to allegations of materially misleading business information [1] Group 1: Legal Action and Investor Rights - Shareholders of Encompass Health may be entitled to compensation through a class action without any out-of-pocket fees, as the Rosen Law Firm prepares to seek recovery of investor losses [2] - Investors can join the prospective class action by submitting a form or contacting the law firm directly [2] Group 2: Company Performance and Market Reaction - A New York Times article highlighted serious incidents of patient harm and below-average performance on key safety measures at Encompass Health, leading to a 10.3% drop in the company's stock price on July 15, 2025 [3] Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field, including being ranked No. 1 for securities class action settlements in 2017 [4] - The firm has recovered hundreds of millions of dollars for investors, with over $438 million secured in 2019 alone [4]

Core Viewpoint - Rosen Law Firm is reminding purchasers of XPLR Infrastructure, LP common units of a class action lawsuit with a lead plaintiff deadline of September 8, 2025, for those who bought units between September 27, 2023, and January 27, 2025 [1] Group 1: Class Action Details - Investors who purchased XPLR common units during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6] - Investors wishing to serve as lead plaintiff must file with the Court by September 8, 2025 [3] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions for investors [4] - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [4] Group 3: Case Allegations - The lawsuit alleges that XPLR made false and misleading statements regarding its operations as a yieldco, including struggles to maintain operations and the unsustainability of its business model [5] - It is claimed that XPLR entered financing arrangements while downplaying risks, which ultimately led to a halt in cash distributions to investors [5] - The lawsuit asserts that the public statements made by the defendants were materially false and misleading, resulting in investor damages when the truth was revealed [5]